FDA Approves Retevmo for Some Adults and Children With Thyroid Cancer

The Food and Drug Administration (FDA) has granted traditional approval to Retevmo (selpercatinib) for the treatment of adult and pediatric patients 2 years old and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, if radioactive iodine is appropriate, the agency has announced.

Read more: https://www.curetoday.com/view/fda-approves-retevmo-for-some-adults-and-children-with-thyroid-cancer